PMC9524479_01
Episode timeline of case 1. CRP, C-reactive protein; PCT, procalcitonin; ANC, absolute neutrophil count; MRP, meropenem; MIC, micafungin; CPS, cefoperazone sulfate; POS, posaconazole; LZD, linazolamide; TGC, tigecycline; PBS, polymyxin B sulfate; GCV, ganciclovir; AmBL, amphotericin B liposome; VCZ, voriconazole; MOX, moxalactam; CLM, clindamycin; ACV, acyclovir; ABCD, amphotericin B cholesterol sulfate complex.
fcimb-12-960766-g001.jpg
PMC9524479_01_fcimb-12-960766-g001.jpg
f1
A timeline of the episodes is shown in  Figure 1 .
Magnetic resonance imaging (MRI) and computed tomography (CT) images of the patient's head (case 1). (A) MRI of the patient's head on July 17: abnormal signal shadow of the ethmoid sinus, sphenoid sinus, and bilateral maxillary sinus. (B) CT scans of nasopharynx on July 24: soft tissue shadows are observed in the right nasopharynx, ethmoid sinus, nasal cavity, and maxillary sinus.
fcimb-12-960766-g002.jpg
PMC9524479_01_fcimb-12-960766-g002.jpg
f2
The magnetic resonance imaging results of the patient's brain showed abnormal signal shadows of the ethmoid sinus, sphenoid sinus, and bilateral maxillary sinus, considering sinus infections ( Figure 2 ). The CT scans of the nasopharynx showed soft tissue shadows in the right nasopharynx, ethmoid sinus, nasal cavity, and maxillary sinus; fortunately, bone destruction was not found ( Figure 2 ).
PMC9524479_02
Episode timeline of case 2. CRP, C-reactive protein; PCT, procalcitonin; CCU, coronary heart disease care unit; LZD, linazolamide; PTZ, piperacillin sodium and tazobactam; MIC, micafungin; CPS, cefoperazone sulfate; VCZ, voriconazole; MRP, meropenem; AMK, amikacin sulfate; GCV, ganciclovir; ABCD, amphotericin B cholesterol sulfate complex.
fcimb-12-960766-g003.jpg
PMC9524479_02_fcimb-12-960766-g003.jpg
f3
He developed a skin infection after applying the restraint belt.  Figure 3  depicts a timeline of the episodes.
Changes in cutaneous fungal infection (case 2). (A) Admitted. (B) November 1. (C) November 4. (D) Admitted. (E) November 4.
fcimb-12-960766-g004.jpg
PMC9524479_02_fcimb-12-960766-g004.jpg
f4
On the left lower leg, there was a 5 x 6-cm erosion surface ( Figure 4 ). The antiviral treatment began with ganciclovir (0.375 g/12 h, IV), and the antifungal treatment was adjusted to ABCD (150 mg daily, IV). Local debridement and antifungal medication were also initiated. The body temperature was stabilized after 3 days of treatment, and the local symptoms were reduced dramatically ( Figure 4B ). With continuing therapy, the necrotic tissue progressively peeled off, and fresh granulation tissue formed ( Figures 4C, E ).